Securities code: Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) securities abbreviation: Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Announcement No.: 2022019 Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Announcement on the completion of performance commitments of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd. in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) (hereinafter referred to as “the company”) approved the issuance of shares by Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Xincai Co., Ltd. to Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Group Co., Ltd. to purchase assets on February 4, 2020 in accordance with the reply of China Securities Regulatory Commission (zjxk [2020] No. 116) on January 16, 2020, The company completed the transfer of 100% equity of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd. (hereinafter referred to as ” Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical”) and the registration procedures for the change of industrial and commercial equity. Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical became a wholly-owned subsidiary of the company and completed the listing of shares on March 5.
1、 Performance commitment
According to the profit forecast compensation agreement and its supplementary agreement signed by all parties to the transaction, the performance commitment is Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Group Co., Ltd., Zhao Shouming, Zhuang Hui, Wenling Huibang Investment Consulting Co., Ltd. and Wenling Fubang Investment Consulting Co., Ltd., and the performance commitment period is 4 years, i.e. 2019, 2020, 2021 and 2022, The performance promisor promises that the net profit of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical from 2019 to 2022 (i.e. the net profit attributable to the owner of the parent company, subject to the net profit after deducting non recurring profits and losses audited by an accounting firm with securities qualification) will not be less than RMB 184.5 million, RMB 226.5 million, RMB 263.8 million and RMB 312.5 million respectively.
2、 Performance commitments of previous years
According to the audit, the audited net profit attributable to the shareholders of the parent company of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical in 2020 after deducting non recurring profits and losses was 2346403 million yuan, exceeding the commitment of 8.1403 million yuan, completing 103.59% of the performance commitment of this year and realizing the performance commitment of 2020.
3、 Completion of performance commitments in this year
Dahua Certified Public Accountants (special general partnership) reviewed and issued the audit report of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd. (dhsz [2022] No. 009377) and the statement of achievement of performance commitment of Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd. in 2021 issued by Dahua Certified Public Accountants (special general partnership), The net profit attributable to the parent company after the completion of the audit of the non recurring profit and loss of RMB 1.03 million is more than RMB 1 million yuan.
It is hereby announced.
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) board of directors
April 14, 2002
